- Cassava Sciences shares are +3,300% in the past year, but the upside could continue until the $4.5bn market cap biotech achieves a >$50bn valuation.
- Cassava is developing an Alzheimer's therapy in Simufilam that early data suggests may be able to reverse cognitive decline, rather than slowing it.
- Cassava's nine-month data from an open-label trial will be released Thursday, and if it's as strong as at six months, the stock price ought to surge.
- Simufilam's path to approval looks clear, with two pivotal Phase 3 trials set to begin shortly. The drug is orally administered and presents a strong safety profile - in most respects, it appears an improvement on Biogen's Aduhelm.
- It's still early days and nobody should get carried away by Phase 2 data from 50 patients, but if Thursday's data is encouraging there's no question Cassava stock is 25%-50% undervalued.
For further details see:
Cassava Sciences: Critical Alzheimer's Data Due Thursday Offers Upside Potential